| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 7.243.433 | 9.212.291 | 10.669.956 | 10.017.921 | 10.693.565 | 12.334.575 | 13.989.778 | 16.735.336 | 17.250.364 | 22.027.513 |
| Total Income - EUR | 7.277.399 | 9.255.075 | 10.730.601 | 10.023.905 | 10.721.055 | 12.371.754 | 14.125.689 | 16.803.765 | 17.270.543 | 22.111.857 |
| Total Expenses - EUR | 7.147.204 | 8.080.568 | 9.357.126 | 9.041.059 | 9.439.497 | 10.015.028 | 13.357.301 | 14.943.994 | 14.552.043 | 17.889.846 |
| Gross Profit/Loss - EUR | 130.195 | 1.174.507 | 1.373.476 | 982.846 | 1.281.558 | 2.356.726 | 768.387 | 1.859.771 | 2.718.500 | 4.222.011 |
| Net Profit/Loss - EUR | 76.708 | 997.135 | 1.107.704 | 831.523 | 1.093.516 | 2.007.118 | 663.869 | 1.501.243 | 2.333.291 | 3.718.673 |
| Employees | 57 | 67 | 72 | 73 | 71 | 69 | 68 | 71 | 69 | 72 |
Check the financial reports for the company - Quantumpharm Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.212.191 | 2.122.999 | 1.946.902 | 1.706.717 | 1.579.086 | 1.416.174 | 1.745.122 | 1.590.522 | 1.975.279 | 1.677.164 |
| Current Assets | 5.681.056 | 5.874.963 | 6.320.046 | 6.601.939 | 7.058.720 | 8.294.768 | 8.863.520 | 11.835.568 | 9.555.230 | 16.619.619 |
| Inventories | 1.405.315 | 1.590.643 | 1.349.375 | 1.863.219 | 1.913.495 | 2.116.030 | 2.909.172 | 4.094.786 | 3.568.405 | 5.319.826 |
| Receivables | 3.490.922 | 3.846.896 | 4.352.390 | 4.201.704 | 4.106.341 | 4.766.372 | 4.932.731 | 6.973.221 | 5.433.969 | 10.571.833 |
| Cash | 784.818 | 437.425 | 618.282 | 537.015 | 1.038.884 | 1.412.365 | 1.021.617 | 767.562 | 552.856 | 727.961 |
| Shareholders Funds | 2.250.741 | 1.360.048 | 2.444.738 | 3.123.950 | 1.365.105 | 3.346.344 | 3.925.944 | 1.762.584 | 2.597.549 | 3.994.449 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 5.646.928 | 6.646.228 | 5.823.597 | 5.193.144 | 7.272.701 | 6.367.129 | 6.685.155 | 11.676.730 | 8.939.031 | 14.302.872 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4690 - 4690" | |||||||||
| CAEN Financial Year |
4690
|
|||||||||
Comments - Quantumpharm Srl